Fred Hutch spinout Faraday Pharmaceuticals raises $25M (up to $30M) to advance iodide drug preventing reperfusion injury and muscle loss
Faraday Pharmaceuticals, a Fred Hutch spinout, has raised $25 million (potentially up to $30 million) to develop an iodide-based drug to prevent reperfusion injury after heart attacks and ultimately limit skeletal muscle loss in stressed or bedridden patients.